AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives: Difference between revisions
No edit summary |
|||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AO}} | {{CMG}}; {{AE}} {{AO}} | ||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)<ref name="pmid24503673">{{cite journal| author=Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL et al.| title=Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. | journal=Stroke | year= 2014 | volume= | issue= | pages= | pmid=24503673 | doi=10.1161/01.str.0000442009.06663.48 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24503673 }} </ref> == | |||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == | |||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" |
Revision as of 20:07, 13 February 2014
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
FDA on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
CDC on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives in the news | |
Blogs on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)[1]
Class III (No Benefit) |
"1. OCs may be harmful in women with additional risk factors (eg, cigarette smoking, prior thromboembolic events) (Level of Evidence: B) " |
"2. Routine screening for prothrombotic mutations before initiation of hormonal contraception is not useful. (Level of Evidence: A) " |
Class I |
" Measurement of BP before initiation of hormonal contraception is recommended. (Level of Evidence: B) " |
Class IIb |
" Among OC users, aggressive therapy of stroke risk factors may be reasonable. (Level of Evidence: C)" |
References
- ↑ Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL; et al. (2014). "Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. doi:10.1161/01.str.0000442009.06663.48. PMID 24503673.